Mounjaro Price Hike & Ozempic/Wegovy Update: Brazil Drug Costs 2024

The ripple effects of pharmaceutical pricing decisions are being felt globally, and now, right here in Austin, Texas. As of Wednesday, April 1st, 2026, Eli Lilly is increasing the price of Mounjaro (tirzepatide), a medication widely used for both type 2 diabetes and weight loss. While Novo Nordisk, the manufacturer of Ozempic and Wegovy (both containing semaglutide), is currently holding steady on their prices, the situation underscores a growing concern for Austinites managing their health and healthcare budgets.

Understanding the Price Adjustments and Regulatory Framework

The price hike for Mounjaro is authorized by the Câmara de Regulação do Mercado de Medicamentos (CMED) in Brazil, but the implications extend beyond international markets. The core issue revolves around how pharmaceutical companies navigate price controls and market competition. According to the Agência Nacional de Vigilância Sanitária (Anvisa), the CMED sets price ceilings, but manufacturers and pharmacies have leeway to price within those limits. This creates a complex landscape where the final cost to the consumer can vary.

The medications in question – Mounjaro, Ozempic, and Wegovy – fall into a category with limited competition, allowing for price increases of up to 1.13% according to the CMED’s tiered system. This is particularly relevant for those relying on these medications for chronic conditions. The price adjustments apply to the “factory price,” the maximum price charged to the government, and the price consumers pay at the pharmacy. It’s crucial to note that these figures don’t include taxes, which will add to the final cost.

Current Price Ranges (as of April 1, 2026)

Here’s a breakdown of the price ranges, based on information available as of today:

• Mounjaro (Tirzepatide): Before the re-adjustment, the factory price ranged from R$423.66 to R$3,680.86. With the 1.13% increase, the novel maximum factory price is approximately R$428.44 to R$3,722.45.
• Ozempic & Wegovy (Semaglutide): Novo Nordisk is currently maintaining factory prices between R$794.47 and R$1,987.84 (for Ozempic) and R$794.47 and R$1,031.78 (for Wegovy), while they evaluate the CMED resolution.

These prices are subject to change and vary based on dosage. The situation highlights the need for Austinites to stay informed about their medication costs and explore available options.

The Broader Context: Tirzepatide, Semaglutide, and the Weight Loss Medication Landscape

Both tirzepatide (Mounjaro/Zepbound) and semaglutide (Ozempic/Wegovy) are incretin-based therapies, meaning they mimic the effects of natural hormones that regulate blood sugar, and appetite. Tirzepatide, a dual GIP and GLP-1 receptor agonist, has demonstrated particularly promising results in clinical trials, often showing greater efficacy for both weight loss and glycemic control compared to semaglutide, a GLP-1 receptor agonist. A study published in JAMA Internal Medicine in July 2024 compared usage rates of the two medications between May 2022 and September 2023, revealing significant demand for both.

The increased demand, coupled with supply chain challenges and now, price fluctuations, is creating a complex situation for patients and healthcare providers. Switching between these medications, as discussed in a December 2025 article in the Pharmaceutical Journal, requires careful consideration of dosage equivalency, washout periods, and individual patient responses. The recent price increase of Mounjaro, and the subsequent stockpiling, underscores the importance of clear communication and support from healthcare providers.

Here in Austin, the impact is particularly noticeable given the city’s growing population and increasing focus on health and wellness. Many Austinites utilize Central Health, the local healthcare district, and the rising cost of these medications could strain resources and limit access for those who need them most. The University of Texas at Austin’s Dell Medical School is a leading research institution in the field of metabolic health, and its physicians are likely seeing firsthand the challenges patients face navigating these changes.

Navigating the Changes: A Local Resource Guide for Austinites

Given my background in healthcare administration and a deep understanding of the pharmaceutical market, if these price increases are impacting you in Austin, here are three types of local professionals you should consider consulting:

1. Certified Diabetes Care and Education Specialists (CDCES):

A CDCES can help you understand your medication options, develop a personalized management plan, and explore potential cost-saving strategies. Look for a specialist with experience in both type 2 diabetes and weight management, and verify their credentials through the Certification Board for Diabetes Care and Education. Many CDCES work within the St. David’s Healthcare system here in Austin.

2. Pharmacists Specializing in Compounding:

Compounding pharmacies can sometimes create customized formulations of medications, potentially offering cost savings or addressing supply issues. Ensure the compounding pharmacy is licensed and accredited by the Pharmacy Compounding Accreditation Board (PCAB). Several independent pharmacies around South Congress Avenue offer compounding services.

3. Patient Advocates/Medical Billing Specialists:

These professionals can navigate the complexities of insurance coverage, negotiate with pharmaceutical companies, and identify financial assistance programs. Look for an advocate with a proven track record and a thorough understanding of the healthcare system in Texas. Organizations like the Texas Health and Human Services Commission can also provide guidance.

Ready to find trusted professionals? Browse our complete directory of top-rated healthcare experts in the Austin area today.